; or (ii) 25 percent or more over a 36-month period beginning on or after January 1, 2024; or (B) the wholesale acquisition price of the qualifying drug for the applicable year or per normal course of treatment that lasts less than 1 year, as determined by the Secretary, exceeds United States median household income beginning on or after January 1, 2024. (2) Report deadline Each report described in paragraph (1) shall be submitted to the Secretary not later than 30 days prior to the planned effective date of such price increase. (c) Contents A report under subsection (b) shall, at a minimum, include— (1) with respect to the qualifying drug— (A) the percentage by which the manufacturer will raise the wholesale acquisition cost of the drug on the planned effective date of such price increase, as applicable; (B) a justification for, and description of, each manufacturer’s price increase that will occur during the 12-month period described in subsection (b)(1)(A) or the 36-month period described in subsection (b)(1)(B), as applicable; (C) an explanation for, and description of, the cost associated with a qualifying drug if such drug meets the criteria under subsection (b)(1)(B), as applicable; (D) the identity of the initial developer of the drug; (E) a description of the history of the manufacturer's price increases for the drug since the approval of the application for the drug under section 505 of the Federal Food, Drug, and Cosmetic Act or the issuance of the license for the drug under section 351, or since the manufacturer acquired such approved application or license, as applicable; (F) the current list price of the drug; (G) the total expenditures of the manufacturer on— (i) materials and manufacturing for such drug; and (ii) acquiring patents and licensing for such drug; (H) the percentage of total expenditures of the manufacturer on research and development for such drug that was derived from Federal funds